Training + Education

The Center for the Evaluation of Value and Risk in Health (CEVR) is committed to educating decision makers, researchers and practitioners from academia, industry, and government, and other stakeholders in the field of comparative and cost effectiveness analysis of medical interventions through its symposia, presentations, and publications.

Health Policy Seminar: Value, Benefits and Risks

The Center for the Evaluation of Value and Risk in Health, led by Dr. Peter Neumann, and the Division of Clinical Decision Making, Informatics and Telemedicine, led by Dr. John Wong, are co-sponsoring the Health Policy Seminar Series at Tufts Medical Center.  The focus of this series is on clinical decision making, risk assessment, and economic evaluation of public health policy.

The purpose of this seminar series is to keep current with developments in this field, consider applications to practice, and provide a forum for discussion.  The audience has varying levels of familiarity with risk and decision science methodology and includes researchers from the Institute for Clinical Research & Health Policy Studies and other interested members of the Tufts Medical Center community, as well as the greater Boston area.

Upcoming Seminars

April 8, 2013
Bruce Landon, MD, MBA, Harvard Medical School
Comparing Medicare Advantage and Traditional Medicare: Use of Services and Quality

March 18, 2013
Jonathan Levy, ScD, Harvard University
The health and economic impacts of home-based interventions on pediatric asthma: A discrete event simulation model

November 30, 2012
Claire Wang, MD, ScD, Columbia University
The Obesity Epidemic and Policy Interventions to Reduce Excess Calories: Soda Taxes, a Case Study

November 9, 2012
Jacob Leshno, PhD, Harvard University
Matching patients to services in congested waiting lists

October 9, 2012
Kyle Hvidsten, MPH, Vertex Pharmaceuticals
The Changing Face of Health Economics and Outcomes Research: An Industry Perspective

June 20, 2012
Niteesh K. Choudhry, MD, PhD, Harvard Medical School and Brigham and Women’s Hospital
Is FREEE cheap enough? Addressing the epidemic of non-adherence to essential medications

March 5, 2012
John F. P. Bridges, PhD, Johns Hopkins Bloomberg School of Public Health
Patient-Centered Outcomes Research – A Learning-By-Doing Process

February 8, 2012
Donald S. Shepard, PhD, Brandeis University
Cost Effectiveness of Cardiac Rehabilitation in Older Coronary Patients

October 31, 2011
Robert S. Woodward, PhD, University of New Hampshire
A Straight and Narrow Path to Hope? Rationalizing Some of Our Nation’s Rising Health Care Expenditures

September 19, 2011
Natasha Stout, PhD, Harvard Medical School
Filling Evidence Gaps in Breast Cancer Screening Policy: Examples from CISNET

July 11, 2011
David C. Grabowski, PhD, Harvard Medical School
Effect of Nursing Home Ownership on Quality of Care: An Instrumental Variables Approach

April 4, 2011
Michael Chernew, PhD, Harvard Medical School
Evaluating the Alternative Quality Contract

March 2, 2011
Kimberly Thompson, ScD, President, Kid Risk, Inc.
The Economics of Disease Eradication: Insights from Modeling the Complexities of Polio

November 29, 2010
Sarah Garner, PhD, National Institute for Health and Clinical Excellence (NICE), UK
Managing Healthcare at NICE: Perspectives from “Across the Pond”

September 27, 2010
David Cutler, PhD, Harvard University
Implications of Health Care Reform for Clinical Decision-Making

July 7, 2010
Sean D. Sullivan, PhD, University of Washington
Performance-based Reimbursement Schemes for Medical Technology: Taxonomy, Experience and Lessons-Learned

April 1, 2010
Uwe Siebert, MD, MPH, MSc, ScD, University of Health Sciences, Medical Informatics and Technology
The Assessment of Benefits, Harm and Cost Effectiveness of Health Technologies in Germany – Key Principles and Results of a Pilot Study

February 25, 2010
Michael Drummond, BSc, MCom, DPhil, University of York
NICEly Does It: Recent Developments in the Use of Health Technology Assessment in the UK

January 21, 2010
Ava John-Baptiste, AHRQ
Treatment of Chronic Hepatitis C in Patients with Substance Abuse: The rules have changed, but why aren't patients ready?

October 15, 2009
Martin Buxton, Brunel University
Estimating economic benefits from medical research: Methods and results for the UK; questions for international research policy

July 10, 2009
R. Scott Braithwaite, MD, MSc, Yale University
CEA, Value-based Insurance Design, and Consumers

May 14, 2009
Moshe Leshno, MD, PhD, Tel Aviv University
Stochastic Dominance and Medical Decision Making: Theory and Applications

January 27, 2009
Jens Grueger, PhD, Novartis AG
Market Access for Innovative Medicines: Health technology assessment and incentives for innovation

October 6, 2008
Jaime Caro, MDCM, United BioSource Corporation and McGill University
New German Guidelines for Health Technology Assessments: Boon or Boondoggle?

July 10, 2008
Jane J. Kim, PhD, Harvard School of Public Health
Cost-Effectiveness of Guidelines for HPV vaccination in the US

April 30, 2008
Kenneth A. Freedberg, MD, MSc, Harvard Medical School and School of Public Health
HIV and Decision Science: Informing Guidelines from DC to Durban